Health X Platfor

Which are the latest news on Health X Platfor?

Why is Health X Platform Ltd falling/rising?

As of 05-Sep, Health X Platform Ltd's stock price is at 292.30, showing a slight increase today but a decline of 1.07% over the past week and 7.47% over the past month. The stock is underperforming its sector and trading below its moving averages, indicating a bearish trend amid decreasing investor participation.

As of 05-Sep, Health X Platform Ltd's stock price is currently at 292.30, reflecting a slight increase of 0.6 (0.21%). Despite this small rise today, the stock has shown a negative performance over the past week, with a decline of 1.07%, and a more significant drop of 7.47% over the past month. Year-to-date, the stock has decreased by 1.13%, although it has performed better over the past year with a gain of 7.34%.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 0.87%. Additionally, it has experienced a trend reversal, gaining after two consecutive days of decline. However, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend overall.<BR><BR>Investor participation appears to be falling, as evidenced by a decrease in delivery volume of 2.13k on September 3, which is down by 2.16% compared to the 5-day average. This decline in trading activity may contribute to the stock's overall performance challenges. Despite the minor increase today, the broader context indicates that Health X Platform Ltd is facing headwinds that have led to its recent price fluctuations.

Who are in the management team of Health X Platfor?

The management team of Health X Platfor includes Banwari Lal Mittal (Chairman & Managing Director), Ravi Kant Sharma, Abha Mittal, and Anjana Dikshit (Directors), along with independent directors Parimal Kumar Chattaraj, Rupanjana De, and J. N. Mukhopadhyaya, and Pratap Singh as Company Secretary & Compliance Officer.

The management team of Health X Platfor includes the following individuals:<BR><BR>1. **Banwari Lal Mittal** - Chairman & Managing Director<BR>2. **Ravi Kant Sharma** - Director<BR>3. **Parimal Kumar Chattaraj** - Independent Director<BR>4. **Abha Mittal** - Director<BR>5. **Rupanjana De** - Independent Director<BR>6. **PRATAP SINGH** - Company Secretary & Compliance Officer<BR>7. **J. N. Mukhopadhyaya** - Independent Director<BR>8. **Anjana Dikshit** - Additional Director<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

What does Health X Platfor do?

Health X Platform Ltd is a micro-cap healthcare services company, incorporated in 1989, with recent quarterly net sales of 447 Cr and a net profit of 3 Cr as of June 2026. It has a market cap of INR 961 Cr and key financial metrics include a debt-equity ratio of 0.04 and a return on equity of 0.36%.

Overview: <BR>Health X Platform Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in 1989 as 'Satyam Fiscal Services Private Limited' and underwent several name changes, becoming 'Microsec Financial Services Limited' in 2005 after converting to a public limited company. The most recent quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 447 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 3 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 961 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.04 <BR>Return on Equity: 0.36% <BR>Price to Book: 1.47<BR><BR>Contact Details: <BR>Address: Azimganj House 2nd Floor, 7 Abanindra Nath Thakur Sarani Kolkata West Bengal : 700017 <BR>Tel: 91-33-22829330 <BR>Email: info@sastasundar.com <BR>Website: http://www.sastasundarventures.com

Who are the peers of the Health X Platfor?

Health X Platfor's peers include Suraksha Diagno, 3B Blackbio, Laxmi Dental, One Global Serv, Hemant Surgical, Prevest Denpro, and Nureca. Health X Platfor has below-average management risk and growth, with a 1-year return of 9.14%, outperforming Laxmi Dental but underperforming One Global Serv.

Peers: The peers of Health X Platfor are Suraksha Diagno., 3B Blackbio, Laxmi Dental, One Global Serv, Hemant Surgical, Prevest Denpro, Nureca.<BR><BR>Quality Snapshot: Excellent management risk is observed at Suraksha Diagno. and Prevest Denpro, while Average management risk is found at 3B Blackbio, Laxmi Dental, One Global Serv, Hemant Surgical, and the rest. Below Average management risk is noted for Health X Platfor and Nureca. Growth is Excellent at One Global Serv, Good at Suraksha Diagno., Laxmi Dental, and Hemant Surgical, while Below Average growth is seen at 3B Blackbio, Health X Platfor, Nureca, and the rest. Capital Structure is Excellent for 3B Blackbio, Laxmi Dental, One Global Serv, and Prevest Denpro, while Good is noted for Suraksha Diagno. and Hemant Surgical, and Below Average for Health X Platfor and Nureca.<BR><BR>Return Snapshot: The peer with the highest 1-year return is One Global Serv at 111.18%, while Laxmi Dental has the lowest at -42.71%. Health X Platfor's 1-year return of 9.14% is below that of One Global Serv but above Laxmi Dental. Additionally, the six-month returns are negative for Laxmi Dental, One Global Serv, and Prevest Denpro.

How big is Health X Platfor?

As of 31st August, Health X Platform Ltd has a market capitalization of 961.00 Cr and reported net sales of 1467.69 Cr, with a net loss of 20.19 Cr in the latest four quarters. Shareholder's funds are 669.87 Cr, and total assets amount to 963.16 Cr.

As of 31st August, Health X Platform Ltd has a market capitalization of 961.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Health X Platform reported net sales of 1467.69 Cr. However, the company experienced a loss of 20.19 Cr in net profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's funds are recorded at 669.87 Cr, while total assets amount to 963.16 Cr.

Should I buy, sell or hold Sastasundar Ventures Ltd?

When is the next results date for Sastasundar Ventures Ltd?

The next results date for Sastasundar Ventures Ltd is August 7, 2026.

The next results date for Sastasundar Ventures Ltd is scheduled for August 7, 2026.

Are Sastasundar Ventures Ltd latest results good or bad?

Sastasundar Ventures Ltd's latest Q4 FY26 results are concerning, showing a 30.77% revenue increase to ₹373.78 crores but a net loss of ₹11.17 crores, indicating significant operational and financial challenges despite revenue growth. The negative operating margin and low return on equity further highlight the company's struggles with profitability.

Sastasundar Ventures Ltd's latest results for Q4 FY26 indicate a challenging situation for the company. While the revenue saw a significant year-on-year increase of 30.77%, reaching ₹373.78 crores, the consolidated net profit turned negative, reporting a loss of ₹11.17 crores. This marks a staggering decline of 1,088.50% quarter-on-quarter, reversing the previous quarter's profit.<BR><BR>The operating margin also deteriorated, landing at -6.74%, which is a notable drop from -2.99% in the prior quarter. This suggests that despite the revenue growth, the company is struggling with operational efficiency and profitability. Additionally, the return on equity is a mere 3.66%, which is below the industry average, indicating weak capital efficiency.<BR><BR>Overall, the results reflect a concerning trend where revenue growth is not translating into profitability, raising red flags about the company's ability to sustain its operations effectively. The combination of persistent losses, declining margins, and high valuation multiples presents a challenging outlook for investors. Therefore, the latest results can be characterized as bad, highlighting significant operational and financial challenges.

Is Sastasundar Ven. overvalued or undervalued?

As of December 4, 2025, Sastasundar Ven. is considered very expensive and overvalued, with a PE ratio of 14,101.14 and unfavorable comparisons to peers like Bajaj Finance and Life Insurance, suggesting that investors should exercise caution.

As of 4 December 2025, the valuation grade for Sastasundar Ven. has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios highlight this concern, with a staggering PE ratio of 14,101.14, an EV to EBIT of -13.69, and an EV to EBITDA of -14.80, all suggesting unsustainable valuations relative to its earnings and cash flows.<BR><BR>In comparison to peers, Sastasundar Ven. stands out unfavorably; for instance, Bajaj Finance has a PE of 34.9 and an EV to EBITDA of 19.63, while Life Insurance boasts a much more attractive PE of 10.85 and an EV to EBITDA of 8.92. These comparisons further reinforce the notion that Sastasundar Ven. is overvalued in the current market context. Despite a recent positive performance over the past month compared to the Sensex, the overall valuation metrics indicate that investors should approach this stock with caution.

Is Sastasundar Ven. technically bullish or bearish?

As of December 3, 2025, Sastasundar Ven's technical trend has shifted to bullish, supported by positive daily moving averages, bullish weekly MACD and KST, and mildly bullish Bollinger Bands, indicating favorable momentum despite no signals from the RSI.

As of 3 December 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The daily moving averages are bullish, and the weekly MACD and KST are also bullish, indicating positive momentum. The Bollinger Bands on both weekly and monthly time frames are mildly bullish, suggesting potential upward movement. Despite the lack of signals from the RSI, the overall technical landscape remains favorable for Sastasundar Ven.

How has been the historical performance of Sastasundar Ven.?

Sastasundar Ven.'s historical performance has shown significant fluctuations, with net sales decreasing to 1,110.95 Cr in Mar'25 from 1,375.71 Cr in Mar'24, resulting in a profit after tax of -122.74 Cr in Mar'25, down from 92.03 Cr in Mar'24. The company faced challenges in profitability and asset management during this period.

Answer:<BR>The historical performance of Sastasundar Ven. shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Sastasundar Ven. reported net sales of 1,110.95 Cr in Mar'25, a decrease from 1,375.71 Cr in Mar'24, but an increase from 1,039.81 Cr in Mar'23. The total operating income mirrored this trend, reaching 1,110.95 Cr in Mar'25, down from 1,375.71 Cr in the previous year. The total expenditure, excluding depreciation, was 1,166.98 Cr in Mar'25, down from 1,370.29 Cr in Mar'24. This resulted in an operating profit (PBDIT) of 3.81 Cr in Mar'25, a decline from 65.83 Cr in Mar'24. The profit before tax was -192.86 Cr in Mar'25, compared to 55.68 Cr in Mar'24, leading to a profit after tax of -122.74 Cr in Mar'25, down from 92.03 Cr in Mar'24. The consolidated net profit also fell to -91.17 Cr in Mar'25 from 8.88 Cr in Mar'24. On the balance sheet, total assets decreased to 963.16 Cr in Mar'25 from 1,149.19 Cr in Mar'24, while total liabilities also fell to 963.16 Cr in Mar'25 from 1,149.19 Cr in Mar'24. The cash flow from operating activities was 38 Cr in Mar'24, a recovery from -111 Cr in Mar'23, while the closing cash and cash equivalents increased to 33 Cr in Mar'24 from 31 Cr in Mar'23. Overall, the financial performance of Sastasundar Ven. reflects a challenging environment with notable volatility in profitability and asset management.

Who are the top shareholders of the Sastasundar Ven.?

The top shareholder of Sastasundar Ven. is Banwari Lal Mittal, holding 33.37%. Other shareholders include four foreign institutional investors with 1.6%, individual investors at 13.7%, and the highest public shareholder, Lekh Raj Juneja, with 1.89%.

The top shareholders of Sastasundar Ven. include the promoters, with Banwari Lal Mittal holding the highest stake at 33.37%. There are no pledged promoter holdings. In terms of institutional investors, the company is held by four foreign institutional investors (FIIs) with a combined holding of 1.6%. Additionally, individual investors collectively own about 13.7% of the shares, while the highest public shareholder is Lekh Raj Juneja, who holds 1.89%. Mutual funds currently hold shares through two schemes, but their stake is negligible at 0.0%.

Has Sastasundar Ven. declared dividend?

Sastasundar Ventures Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of July 23, 2012. However, the dividend yield is 0%, and total returns have varied, showing significant gains over the 5-year period despite negative returns in shorter terms.

Sastasundar Ventures Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 23 Jul 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -23.17%, the dividend return was 0%, resulting in a total return of -23.17%.<BR><BR>In the 1-year period, the price return was -10.7%, the dividend return was 0%, leading to a total return of -10.7%.<BR><BR>Over the 2-year period, the price return was -6.26%, the dividend return was 0%, which resulted in a total return of -6.26%.<BR><BR>In the 3-year period, the price return was -13.84%, the dividend return was 0%, culminating in a total return of -13.84%.<BR><BR>For the 4-year period, the price return was 20.91%, the dividend return was 0%, giving a total return of 20.91%.<BR><BR>In the 5-year period, the price return was 227.56%, the dividend return was 0%, resulting in a total return of 227.56%.<BR><BR>Overall, while Sastasundar Ventures Ltd declared a dividend, the dividend yield remains at 0%, indicating no additional income from dividends in recent periods. The total returns show a mixed performance, with significant gains over the long term, particularly in the 5-year period, despite negative returns in the shorter terms.